Literature DB >> 32889987

Emergency department response to COVID-19 outbreak with a fever screening station and "graded approach" for isolation and testing.

Julia Chia-Yu Chang1,2, You-Hsu Chen3, Meng-Chen Lin3, Yi-Jing Li3, Teh-Fu Hsu1,2, Hsien-Hao Huang1,2, David Hung-Tsang Yen1,2,4.   

Abstract

BACKGROUND: Ever since coronavirus disease 2019 (COVID-19) emerged in Wuhan China in December 2019, it has had a devastating effect on the world through exponential case growth and death tolls in at least 146 countries. Rapid response and timely modifications in the ED for infection control are paramount to maintaining basic medical services and preventing the spread of COVID-19. This study presents the unique measure of combining a fever screening station (FSS) and graded approach to isolation and testing in a Taiwanese medical center.
METHODS: An FSS was immediately set up outside the ED on January 27, 2019. A graded approach was adopted to stratify patients into "high risk," "intermediate risk," and "undetermined risk" for both isolation and testing.
RESULTS: A total of 3755 patients were screened at the FSS, with 80.3% visiting the ED from home, 70.9% having no travel history, 21.4% having traveled to Asia, and 10.0% of TVGH staff. Further, 54.9% had fever, 35.5% had respiratory symptoms, 3.2% had gastrointestinal symptoms, 0.6% experienced loss of smell, and 3.1% had no symptoms; 81.3% were discharged, 18.6% admitted, and 0.1% died. About 1.9% were admitted to the ICU, 10.3% to the general ward, and 6.4% were isolated. Two patients tested positive for COVID-19 (0.1%) and 127 (3.4%) tested positive for atypical infection; 1471 patients were tested for COVID-19; 583 were stratified as high-risk, 781 as intermediate-risk, and 107 as undetermined-risk patients.
CONCLUSION: Rapid response for infection control is paramount in the ED to confront the COVID-19 outbreak. The FFS helped divide the flow of high- and intermediate-risk patients; it also decreased the ED workload during a surge of febrile patients. A graded approach to testing uses risk stratification to prevent nosocomial infection of asymptomatic patients. A graded approach to isolation enables efficient allocation of scarce medical resources according to risk stratification.

Year:  2020        PMID: 32889987     DOI: 10.1097/JCMA.0000000000000420

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  13 in total

1.  Ethical issues in the response to Ebola virus disease in United States emergency departments: a position paper of the American College of Emergency Physicians, the Emergency Nurses Association, and the Society for Academic Emergency Medicine.

Authors:  Arvind Venkat; Shellie L Asher; Lisa Wolf; Joel M Geiderman; Catherine A Marco; Jolion McGreevy; Arthur R Derse; Edward J Otten; John E Jesus; Natalie P Kreitzer; Monica Escalante; Adam C Levine
Journal:  Acad Emerg Med       Date:  2015-04-22       Impact factor: 3.451

2.  A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.

Authors:  Vincent J Munster; Marion Koopmans; Neeltje van Doremalen; Debby van Riel; Emmie de Wit
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

3.  Impact of severe acute respiratory syndrome (SARS) outbreaks on the use of emergency department medical resources.

Authors:  Chien-Cheng Huang; David Hung-Tsang Yen; Hsien-Hao Huang; Wei-Fong Kao; Lee-Min Wang; Chun-I Huang; Chen-Hsen Lee
Journal:  J Chin Med Assoc       Date:  2005-06       Impact factor: 2.743

4.  [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].

Authors: 
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2020-02-10

5.  Protecting Healthcare Workers During the Coronavirus Disease 2019 (COVID-19) Outbreak: Lessons From Taiwan's Severe Acute Respiratory Syndrome Response.

Authors:  Jonathan Schwartz; Chwan-Chuen King; Muh-Yong Yen
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

6.  Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.

Authors:  Zhiliang Hu; Ci Song; Chuanjun Xu; Guangfu Jin; Yaling Chen; Xin Xu; Hongxia Ma; Wei Chen; Yuan Lin; Yishan Zheng; Jianming Wang; Zhibin Hu; Yongxiang Yi; Hongbing Shen
Journal:  Sci China Life Sci       Date:  2020-03-04       Impact factor: 10.372

7.  Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China.

Authors:  Sebastian Hoehl; Holger Rabenau; Annemarie Berger; Marhild Kortenbusch; Jindrich Cinatl; Denisa Bojkova; Pia Behrens; Boris Böddinghaus; Udo Götsch; Frank Naujoks; Peter Neumann; Joscha Schork; Petra Tiarks-Jungk; Antoni Walczok; Markus Eickmann; Maria J G T Vehreschild; Gerrit Kann; Timo Wolf; René Gottschalk; Sandra Ciesek
Journal:  N Engl J Med       Date:  2020-02-18       Impact factor: 91.245

8.  Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).

Authors:  Jaffar A Al-Tawfiq
Journal:  Travel Med Infect Dis       Date:  2020-02-27       Impact factor: 6.211

9.  Analysis of Imported Cases of COVID-19 in Taiwan: A Nationwide Study.

Authors:  Jui-Yao Liu; Tzeng-Ji Chen; Shinn-Jang Hwang
Journal:  Int J Environ Res Public Health       Date:  2020-05-09       Impact factor: 3.390

10.  Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020.

Authors:  Emanuele Nicastri; Alessandra D'Abramo; Giovanni Faggioni; Riccardo De Santis; Andrea Mariano; Luciana Lepore; Filippo Molinari; Giancarlo Petralito; Silvia Fillo; Diego Munzi; Angela Corpolongo; Licia Bordi; Fabrizio Carletti; Concetta Castiletti; Francesca Colavita; Eleonora Lalle; Nazario Bevilacqua; Maria Letizia Giancola; Laura Scorzolini; Simone Lanini; Claudia Palazzolo; Angelo De Domenico; Maria Anna Spinelli; Paola Scognamiglio; Paolo Piredda; Raffaele Iacomino; Andrea Mone; Vincenzo Puro; Nicola Petrosillo; Antonio Battistini; Francesco Vairo; Florigio Lista; Giuseppe Ippolito
Journal:  Euro Surveill       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.